Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of “Hold” from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has earned a consensus rating of “Hold” from the twenty-six brokerages that are currently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $25.0909.

SRPT has been the topic of several research reports. Oppenheimer reiterated an “outperform” rating and issued a $37.00 price target on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Weiss Ratings cut shares of Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, June 29th. Mizuho upped their price objective on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday. Finally, Zacks Research cut shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors have recently modified their holdings of SRPT. Assenagon Asset Management S.A. acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at about $8,165,000. Bank of America Corp DE grew its holdings in Sarepta Therapeutics by 26.6% during the first quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock worth $46,695,000 after acquiring an additional 450,336 shares during the period. Bull Harbor Capital LLC purchased a new position in Sarepta Therapeutics during the first quarter valued at approximately $398,000. ADAR1 Capital Management LLC raised its position in Sarepta Therapeutics by 807.8% during the first quarter. ADAR1 Capital Management LLC now owns 262,058 shares of the biotechnology company’s stock valued at $5,702,000 after acquiring an additional 233,192 shares in the last quarter. Finally, California State Teachers Retirement System lifted its holdings in Sarepta Therapeutics by 27.6% in the first quarter. California State Teachers Retirement System now owns 120,686 shares of the biotechnology company’s stock valued at $2,626,000 after acquiring an additional 26,141 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Up 1.5%

Sarepta Therapeutics stock opened at $20.52 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.62 and a current ratio of 4.63. The business’s 50-day simple moving average is $17.79 and its two-hundred day simple moving average is $19.29. The company has a market cap of $2.17 billion, a PE ratio of -21.38, a PEG ratio of 0.21 and a beta of 0.21. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.15 million. During the same period last year, the business posted ($3.42) earnings per share. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. Equities analysts anticipate that Sarepta Therapeutics will post 3.95 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.